Venetoclax Basket Trial for High Risk Hematologic Malignancies
Public ClinicalTrials.gov record NCT05292664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
Study identification
- NCT ID
- NCT05292664
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Andrew E. Place, MD
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
- Acute Leukemia of Ambiguous Lineage
- Acute Leukemia of Ambiguous Lineage in Relapse
- Acute Lymphoblastic Leukemia With Failed Remission
- Acute Lymphoblastic Leukemia, in Relapse
- Lymphoblastic Lymphoma, Refractory
- Lymphoblastic Lymphoma, in Relapse
- Myelodysplastic Syndromes, Previously Treated
- Myelodysplastic Syndromes, Secondary
- Myelodysplastic Syndromes, de Novo
- Therapy-Related Myelodysplastic Syndrome
- Treatment-Related Acute Myeloid Leukemia
Interventions
- Azacitidine Drug
- Calaspargase Pegol Drug
- Cytarabine Drug
- Dexamethasone Drug
- Dexrazoxane Drug
- Doxorubicin Drug
- Erwinia asparaginase Drug
- Hydrocortisone Drug
- Leucovorin Drug
- Methotrexate Drug
- Venetoclax Drug
- Vincristine Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 40 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2023
- Primary completion
- Jul 1, 2028
- Completion
- Jul 1, 2030
- Last update posted
- Mar 11, 2026
2023 – 2030
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco-Benioff Children's Hospital | San Francisco | California | 94158 | Recruiting |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | Recruiting |
| Children's Healthcare of Atlanta at Arthur M. Blank Hospital | Atlanta | Georgia | 30329 | Recruiting |
| Ann & Robert H Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05292664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05292664 live on ClinicalTrials.gov.